A monoclonal antibody for the treatment of HIV multi-drug-resistant patients, and is a last-line therapy for HIV/AIDS.

Trogarzo® (ibalizumab, TMB-355, TNX-355, Hu5A8) is a biologic that can block the entry of HIV into host cells.
Trogarzo®is an attachment inhibitor and specifically binds to the second extracellular domain of the CD4 receptor.
Trogarzo®can prevent the transmission of HIV via cell-cell fusion while preserving the body's immune function.

A monoclonal antibody protein drug for the treatment of HIV multi-drug-resistant patients, and is a last-line therapy for HIV/AIDS.

Product Function Description

TROGARZO® (ibalizumab, TMB-355, TNX-355, Hu5A8)is the first humanized monoclonal antibody used for HIV infection, blocking the virus from entering cells while preserving immune function. The IV Push is a rapid administration option of Trogarzo® and is one of the FDA-approved administration methods.

TMB-365 is the second-generation Trogarzo® monoclonal antibody used for HIV treatment and prevention. It exhibits better drug resistance and efficacy compared to Trogarzo®. Developed by a team led by Dr. David Ho, TaiMed holds exclusive global rights for its development and marketing.

Product Function Description

• The V5-glycan on HIV-1 gp120 is crucial for Trogarzo® in inhibiting HIV-1 infection.
• After binding to the CD4 receptor, Trogarzo® creates a steric hindrance that prevents conformational changes in the V5-glycan, thereby blocking HIV-1 from infecting T cells.
• Some HIV-1 strains without V5-glycan, leading to reduced sensitivity to Trogarzo® and the development of drug resistance.
• TMB-365 is an improved version of Trogarzo®, with the addition of glycan on the light chain, enhancing its effectiveness against HIV-1.
• TMB-365 exhibits similar binding capability to the CD4 receptor as Trogarzo®, creating steric hindrance regardless of the presence of glycan in the V5-glycan, thus preventing HIV-1 from infecting T cells.

TMB-380 is a broadly neutralizing monoclonal antibody drug with high potent, broad spectrum, and long-lasting effects against HIV-1. When used in combination with TMB-365, it becomes part of a dual therapy against HIV.

Product Function Description

• TMB-365 and TMB-380 superior antiviral activities, with pharmacokinetic profile indicating the potential of dosing bi-monthly or quarterly.
• TaiMed has developed a phase 1b/2 clinical trial of TMB-365 /TMB-380 combination, and submitted an IND application to the US FDA in 2022.
• A phase 1b/2a clinical trial with adaptive design was proposed for viral-suppressed HIV-1 patients. The study will investigate the safety and efficacy of the TMB-365 /TMB-380 combination at different dose levels every 8 or 12 weeks.

Antibody-Drug Conjugates, ADCs

Precision Targeting, Limitless Possibilities.

Antibody-Drug Conjugates (ADCs) technology combines small molecule drugs with monoclonal antibodies to achieve precise drug delivery. Our focus lies in HIV treatment, where our ADCs utilize monoclonal antibodies with high binding specificity to CD4+ T cells. This enables accurate delivery of antiretroviral drugs into virus-infected cells, minimizing side effects and widening the therapeutic window, thus offering new hope to patients.